ObsEva SA.

+0.01 (+2.87%)
Products, Restructuring / Reorganization

Obseva Plans To Initiate A Corporate Restructuring

Published: 07/27/2022 11:57 GMT
ObsEva SA. (OBSV) - Obseva Announces Corporate Updates.
Obseva Sa - Plans to Initiate a Corporate Restructuring and Refocus Company's Development and Commercialization Strategy.
Obseva Sa - Believes Changes Necessary Due to Commercial Landscape.
Obseva Sa - Believes Changes Necessary Due to Potential Additional Capital Needed to Fund Completion of Linzagolix Clinical Development Program.
Obseva Sa - FDA Has Notified Company of Review Issues Regarding Deficiencies in New Drug Application (nda) for Linzagolix for Uterine Fibroids.
Obseva Sa - Review Issues Preclude Discussion of Labeling and Post-marketing Commitments at This Time.
Obseva Sa - Continues to Engage in Communications With FDA.
Obseva Sa - Believes That Resolution of Identified Review Issues May Not Be Feasible by September 13, 2022 Target Action Date.
Obseva Sa - Board Has Decided to Terminate License Agreement With Kissei for Linzagolix.
Obseva Sa - Planned Restructuring to Resize Co to Be Able to Meet Other License Obligations, Assess Strategic Options for Pipeline Development.
Obseva Sa - Intends to Restructure Its Operations to Support Existing License Agreements.
Obseva Sa - Will Assess Strategic Options With Respect to Pipeline Development and Worldwide Rights It Holds for Nolasiban, Excluding China.
Obseva Sa - Final Decision on Extent of Restructuring Will Be Taken Following a Consultation Process With Company's Employees.